The Latest Breaking News from Novo Nordisk

A shocking study in The Lancet showed that nearly three-quarters of U.S. adults are overweight or obese. Chances are that by 2050, there will be 260 million overweight Americans. We already have GLP-1 drugs, and amylin-based drugs are next. Novo Nordisk's compound, Cagrilintide, will be combined with semaglutide in its…

JP Morgan Chase analysts say they’re ‘not surprised’ sector has come ‘under pressure’ since Kennedy’s nomination

Demand for the popular weight loss and diabetes drugs has spiked dramatically in recent years

As drugs emerge as vital to the Government’s anti-obesity strategy, BBC Panorama is shedding light on the pharmaceuticals industry behind them

Shifting blame to the victims of economic policy is an old trick by politicians. Now they’re using obesity to tackle joblessness

Team Novo Nordisk rider among a trio of top Australians in elite men's field

Novo Nordisk’s decision will force people in developing countries to use outdated glass vials and syringes, warn campaigners

Pharmac’s decision to fund continuous glucose monitors and automated insulin delivery systems for the approximately 18,000 people who currently live with type 1 diabetes in Aotearoa New Zealand is good news.

'Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff Sonnenfeld and Steven Tian.